US · Healthcare · Medical Instruments & Supplies
EPS came in at 2.95 against a street estimate of 2.90 — a beat of 1.7%.
Analysts rate ResMed Inc a buy (12 buy, 6 hold, 1 sell out of 19) with an average price target of $246.44.
CONFIDENT ResMed posted Q4 FY26 9% revenue growth, 16% EPS growth, and $1.6B free cash flow. FY27 guides 5–7% organic growth (excluding Astral pause, MatrixCare sale, Noctrix), $12–$12.25 EPS, $1.85B shareholder returns. Astral field action costs ~$75M revenue headwind. Q4 FY2026 Americas constrained by Astral pause; Rest of World growing faster on AirSense 11 global rollout (China launch, Asia-Pac AirCurve launches). No breakdown by segment for RCS given MatrixCare divestiture. Analysts pressed on gross margin near-term weakness vs. full-year expansion (supply chain flywheel + modest pricing to build), price/volume split (management deflected—volume is core), and GLP-1 oral impact (early data shows lower adherence vs. injectables, so tailwind magnitude unclear). Management reiterated volume-driven growth model and patient-first priority on Astral recall. 2026-08-06…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.38% |
| Vanguard Capital Management, LLC | 6.56% |
| Vanguard Portfolio Management, LLC | 5.45% |
| State Street Corp | 4.61% |
| Bank of New York Mellon Corp | 3.41% |
| Geode Capital Management, LLC | 3.02% |
| Morgan Stanley - Brokerage Accounts | 1.86% |
| First Trust Advisors L.P. | 1.58% |
| Document | Date |
|---|---|
| Company announcement · Q1 FY2027 RESMED INC. – 8-K SUMMARY (August 31, 2026) HEADLINE NUMBERS • Company entered accelerated share repurchase (ASR) agreement on August 31, 2026 • Tot | 2026-09-01 |
| Board / officer change · Q1 FY2027 RESMED INC. (RMD) - 8-K FILING SUMMARY HEADLINE NUMBERS • Filing Date: August 17, 2026 (Event Date: August 13, 2026) • Company: ResMed Inc., Delawar | 2026-08-17 |
| Annual report FY2026 RESMED INC. — FORM 10-K FISCAL YEAR ENDED JUNE 30, 2026 HEADLINE NUMBERS • Market capitalization: $34.9 billion (as of December 31, 2025) • Shares o | 2026-08-13 |
| Results announced · Q1 FY2027 RESMED INC. — Q4 FY2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q4 FY2026 revenue: $1.5 billion, up 9% reported (8% constant currency) • Full-year FY202 | 2026-08-06 |
| Results announced · Q4 FY2026 RESMED INC. - 8-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • MatrixCare business sale price: $490 million all-cash transaction • MatrixCare ann | 2026-07-07 |
| Quarterly report · Q3 FY2026 RESMED INC. – QUARTERLY REPORT SUMMARY (Q3 FY2026) HEADLINE NUMBERS • Total net revenue (9M ended March 31, 2026): $4,189,796 thousand ($4.19 billio | 2026-05-01 |
| Quarterly report · Q2 FY2026 RESMED INC. – QUARTERLY REPORT SUMMARY Q2 2026 (Period Ended December 31, 2025) --- HEADLINE NUMBERS • Net Revenue (6 months): $2,758.4 million vs. | 2026-01-30 |
| Quarterly report · Q1 FY2026 RESMED INC. – Q1 FY2026 (ENDED SEPTEMBER 30, 2025) SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Total Revenue: $1,335.6 million (Q1 2025) vs | 2025-10-31 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.66 / share ex-date Aug 20, 2026 · pay Sep 24, 2026 | 2026-08-20 |
| Dividend | $0.60 / share ex-date May 14, 2026 · pay Jun 18, 2026 | 2026-05-14 |
| Dividend | $0.60 / share ex-date Feb 12, 2026 · pay Mar 16, 2026 | 2026-02-12 |
| Dividend | $0.60 / share ex-date Nov 13, 2025 · pay Dec 18, 2025 | 2025-11-13 |
| Dividend | $0.60 / share ex-date Aug 14, 2025 · pay Sep 18, 2025 | 2025-08-14 |
| Announcement | Date |
|---|---|
| Accelerated share repurchase agreement for $450 million announced ResMed announced on August 31, 2026 that it entered into an accelerated share repurchase (ASR) agreement with Citibank to buy back $450 million of its own stock. Here's what this means: WHA | 2026-09-01 |
| Quarterly cash dividend increased 10% to $0.66 per share ResMed's board of directors announced on August 6, 2026, a quarterly cash dividend increase to $0.66 per share, up 10% from the previous quarterly dividend. The dividend will be paid on Sept | 2026-08-06 |
| Quarterly cash dividend of $0.60 per share declared ResMed announced a quarterly cash dividend of $0.60 per share on October 30, 2025. The dividend will be paid on December 18, 2025, to shareholders who own the stock as of the record date of | 2025-10-30 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for ResMed Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.